Healthcare Industry News: IMRT
News Release - October 17, 2007
TomoTherapy Incorporated Announces Strategic Alliance with PTWAdvanced Quality Assurance System for Helical IMRT will be Unveiled at ASTRO 2007
MADISON, Wis.--(HSMN NewsFeed)--TomoTherapy Incorporated (NASDAQ: TTPY ), developer of the TomoTherapy® Hi-Art® treatment system for helical intensity-modulated radiation therapy (IMRT), announced today a strategic alliance with PTW, provider of advanced dosimetry and quality assurance equipment for radiation therapy. The alliance will enable TomoTherapy treatment centers worldwide to verify patient-specific treatment plans with added convenience and efficiency.
"This is another important step for us," said Peter Hoban, senior product manager for TomoTherapy Incorporated. "PTW is an innovative company, providing state-of-the-art quality assurance equipment. This alliance helps TomoTherapy add QA options and workflow enhancements to our integrated platform."
Through the TomoTherapy-PTW alliance, a suite of quality assurance products will be made available to hospitals and cancer centers using TomoTherapy's helical IMRT. The PTW products include the seven29 Ion Chamber Array and the Octavius Octagonal Phantom for film-less, patient-specific quality assurance, as well as the MP3-T Water Phantom for Hi-Art treatment system quality assurance.
"We have developed these tools for the future of IMRT, so it is a natural for us to partner with TomoTherapy," stated Richard Barker, general manager of PTW. "Together, we can ensure consistent precision of the most sophisticated treatment plans in radiation therapy."
Quality is more than a word at PTW. Our purpose is the development, the manufacture and the distribution of products with the highest quality to achieve the greatest possible satisfaction of our customers. PTW's quality assurance system was certified in 1995 as compliant with the standards ISO 9001 and EN 46001. Besides regular internal audits and external audits by DEKRA Certification Systems this quality management system has been successfully checked in the last years by e. g. FDA, UL, VDE and the quality departments of several major customers. To insure the QMS' effectiveness it is continuously updated according to national and international standards. This also implies continuous revision of PTW's quality philosophy, regular employee training, continuous improvement of service and organization as well as continuous support of innovative development in the field of dosimetry.
About TomoTherapy Incorporated
TomoTherapy Incorporated has developed, manufactures and sells the TomoTherapy® Hi-Art® treatment system, an advanced radiation therapy system for the treatment of a wide variety of cancers. The Hi-Art treatment system combines integrated CT imaging with conformal radiation therapy to deliver sophisticated radiation treatments with speed and precision while reducing radiation exposure to surrounding healthy tissue. The company completed its initial public offering in May 2007 and its stock is traded on the NASDAQ Global Market under the symbol TTPY. To learn more about TomoTherapy, please visit our Web site at www.TomoTherapy.com.
Statements in this release regarding future products, events, expectations and other similar matters, including but not limited to statements using the terms "will" or "can" constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements contained in this press release are subject to risks and uncertainties that could cause actual results to differ materially from those anticipated, including but not limited to risks inherent in the development and commercialization of new technology and products, and the other risks listed from time to time in TomoTherapy's filings with the U.S. Securities and Exchange Commission, which by this reference are incorporated herein. These forward-looking statements represent TomoTherapy's judgments as of this date of this press release. TomoTherapy assumes no obligation to update or revise the forward-looking statements in this release because of new information, future events or otherwise.
©2007 TomoTherapy Incorporated. All rights reserved. TomoTherapy, the TomoTherapy logo and Hi-Art and CTrue are among trademarks, service marks or registered trademarks of TomoTherapy Incorporated.
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.